<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02840669</url>
  </required_header>
  <id_info>
    <org_study_id>CM-FA-101</org_study_id>
    <nct_id>NCT02840669</nct_id>
  </id_info>
  <brief_title>A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)</brief_title>
  <official_title>A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adverum Biotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adverum Biotechnologies SAS, a wholly owned subsidiary of Adverum Biotechnologies, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Adverum Biotechnologies, Inc.</source>
  <brief_summary>
    <textblock>
      Friedreich's ataxia (FA) is an autosomal recessive disease with an incidence of 1/50,000 in&#xD;
      the Caucasian population. The main manifestations of FA are progressive sensory and&#xD;
      cerebellar ataxia and cardiomyopathy (CM). It is the most common form of inherited ataxia. A&#xD;
      severe CM affects ~60% of FA patients, mostly young adults, and leads to cardiac failure then&#xD;
      death. Currently, no therapy can change the course of this severe cardiomyopathy.&#xD;
&#xD;
      This study is designed to characterize the cardiac manifestations of FA using cardiac&#xD;
      magnetic resonance (CMR), echocardiography, serum cardiac biomarkers and evaluation of&#xD;
      fatigue severity, in the context of the neurological disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise-stress test</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac magnetic resonance imaging (CMR)</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Echocardiogram</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of cardiac biomarkers in serum</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fatigue Severity Scale</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Friedreich's Ataxia</condition>
  <arm_group>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers (Controls)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac magnetic resonance imaging (CMR)</intervention_name>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
    <arm_group_label>Healthy Volunteers (Controls)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Exercise-stress test</intervention_name>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
    <arm_group_label>Healthy Volunteers (Controls)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Echocardiography (ECHO)</intervention_name>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
    <arm_group_label>Healthy Volunteers (Controls)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac-related blood studies</intervention_name>
    <arm_group_label>Friedreich's Ataxia</arm_group_label>
    <arm_group_label>Healthy Volunteers (Controls)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Friedreich's Ataxia):&#xD;
&#xD;
          -  Males and females;&#xD;
&#xD;
          -  ≥ 18 years old;&#xD;
&#xD;
          -  Willing and able to provide informed consent;&#xD;
&#xD;
          -  Definitive diagnosis of FA, based on clinical phenotype and genotype;&#xD;
&#xD;
          -  With a hypertrophic cardiomyopathy;&#xD;
&#xD;
          -  Ability to complete study assessments.&#xD;
&#xD;
        Exclusion Criteria (Friedreich's Ataxia):&#xD;
&#xD;
          -  Symptoms of cardiac failure;&#xD;
&#xD;
          -  Moderate to severe atrial or ventricular arrhythmias;&#xD;
&#xD;
          -  History of angina pectoris;&#xD;
&#xD;
          -  Inability to undergo cardiac MRI;&#xD;
&#xD;
          -  Clinical history or evidence of diabetes;&#xD;
&#xD;
          -  Abnormal kidney function;&#xD;
&#xD;
          -  Females who are pregnant or nursing;&#xD;
&#xD;
          -  Receipt of an investigational drug within 30 days or 5 half-lives, or active&#xD;
             enrollment in an investigational medication or device study;&#xD;
&#xD;
          -  Inability to sit with back support;&#xD;
&#xD;
          -  Inability to undergo exercise test;&#xD;
&#xD;
          -  Inability to comply with all study requirements;&#xD;
&#xD;
          -  Unaffiliated to any French health insurance or equivalent.&#xD;
&#xD;
        Inclusion Criteria (Healthy Volunteers):&#xD;
&#xD;
          -  Healthy males and females;&#xD;
&#xD;
          -  ≥ 18 years old;&#xD;
&#xD;
          -  Willing and able to provide informed consent;&#xD;
&#xD;
          -  Age and gender matched to the Friedreich's Ataxia group;&#xD;
&#xD;
          -  Ability to complete study assessments.&#xD;
&#xD;
        Exclusion Criteria (Healthy Volunteers):&#xD;
&#xD;
          -  Inability to undergo cardiac MRI;&#xD;
&#xD;
          -  Clinical history or evidence of diabetes;&#xD;
&#xD;
          -  Abnormal kidney function;&#xD;
&#xD;
          -  Females who are pregnant or nursing;&#xD;
&#xD;
          -  Receipt of an investigational drug within 30 days or 5 half-lives, or active&#xD;
             enrollment in an investigational medication or device study;&#xD;
&#xD;
          -  Inability to undergo exercise test;&#xD;
&#xD;
          -  Inability to comply with all study requirements;&#xD;
&#xD;
          -  Unaffiliated to any French health insurance or equivalent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Durr, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Pitié-Salpêtrière, APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière, AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>December 7, 2018</last_update_submitted>
  <last_update_submitted_qc>December 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

